Moderna extends decline after leaked late-stage melanoma vaccine trial data
FROM THE WIRE · FINANCE.YAHOO.COM
Moderna (MRNA) stock slid nearly 2% on Friday, extending its decline for a second day, after leaked data over the biotech company's results from a late-stage trial of its personalized melanoma vaccine. The stock fell as much as 26% on Thursday before closing down more than 17%…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishLeaked trial data on a key vaccine study wiped over $17 billion of market value.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Moderna stock slid nearly 2% after a prior-day drop of more than 17%.
- 02Leaked late-stage melanoma trial figures failed to impress Wall Street.
- 03Full data is scheduled for release Saturday at the Madrid cancer conference.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Moderna, Inc.202.48 USD+1.95%today -0.08%Negative Merck & Co., Inc.144.97 USD+0.92%today -1.55%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets